Personal Home Page

http://www.gmu.edu/departments/lifesciences/proteomics/liotta.htm

Articles in Scholarly Journals [Incomplete List]

1. Smart Hydrogel Particles: Biomarker Harvesting: One-Step Affinity Purification, Size Exclusion, and Protection against Degradation
   Nano Letters, vol. 8, no. 1, pp. 350–361, 2008
2. The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology
   Cancer, vol. 111, no. 3, pp. 173–184, 2007
3. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis
   Hepatology, vol. 46, no. 1, pp. 166–172, 2007
4. A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood
   PROTEOMICS – Clinical Applications, vol. 1, no. 2, pp. 176–184, 2007
5. Physicochemically modified silicon as a substrate for protein microarrays
   Biomaterials, vol. 28, no. 3, pp. 550–558, 2007
6. The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease
   Clinics in Liver Disease, vol. 11, no. 1, pp. 209–220, 2007
7. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
   Nature Reviews Drug Discovery, vol. 6, no. 11, Article ID nrd2381, 9 pages, 2007
8. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance
   Proceedings of the National Academy of Sciences, vol. 104, no. 41, pp. 16158–16163, 2007
9. Correction for Zhou et al., Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance
   Proceedings of the National Academy of Sciences, vol. 104, no. 49, pp. 19655–19656, 2007
10. Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy
    Annals of Surgery, vol. 245, no. 2, pp. 259–266, 2007
11. Differentiation of tumour-stage mycosis fungoides, psoriasis vulgaris and normal controls in a pilot study using serum proteomic analysis
    British Journal of Dermatology, vol. 157, no. 5, pp. 946–953, 2007
12. Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival
    Cancer Research, vol. 67, no. 7, pp. 3431–3440, 2007
13. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study
    Molecular Cancer Therapeutics, vol. 6, no. 3, pp. 820–832, 2007
14. Lysophosphatidic Acid Down-Regulates Stress Fibers and Up-Regulates Pro-Matrix Metalloproteinase-2 Activation in Ovarian Cancer Cells
    Molecular Cancer Research, vol. 5, no. 2, pp. 121–131, 2007
15. Tumor Vascular Proteins As Biomarkers in Ovarian Cancer
    Journal of Clinical Oncology, vol. 25, no. 7, pp. 852–861, 2007
16. Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer
    Annals of Surgical Oncology, vol. 14, no. 9, pp. 2470–2476, 2007
17. A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples
    Clinical Chemistry, vol. 53, no. 6, pp. 1067–1074, 2007
18. Putting the "Bio" back into Biomarkers: Orienting Proteomic Discovery toward Biology and away from the Measurement Platform
    Clinical Chemistry, vol. 54, no. 1, pp. 3–5, 2007
19. Multidimensional metamorphosis of biomarker science
    Expert Review of Molecular Diagnostics, vol. 7, no. 5, pp. 465–467, 2007
20. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine
    Expert Review of Molecular Diagnostics, vol. 7, no. 5, pp. 625–633, 2007
21. Laser capture microdissection technology
    Expert Review of Molecular Diagnostics, vol. 7, no. 5, pp. 647–657, 2007
22. Mathematical Modeling of the Cancer Cell’s Control Circuitry: Paving the Way to Individualized Therapeutic Strategies
    Current Signal Transduction Therapy, vol. 2, no. 2, pp. 145–155, 2007
23. Nanotechnology in clinical proteomics
    Nanomedicine, vol. 2, no. 1, pp. 1–5, 2007
24. Role of proteomics in personalized medicine
    Personalized Medicine, vol. 3, no. 3, pp. 223–226, 2006
25. Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling
    Clinical Cancer Research, vol. 12, no. 3, pp. 791–799, 2006
26. Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analysis
    Cancer Research, vol. 66, no. 3, pp. 1844–1850, 2006
27. Breast Cancer Growth Prevention by Statins
    Cancer Research, vol. 66, no. 17, pp. 8707–8714, 2006
28. Secreted Neutral Metalloproteases of Bacillus anthracis as Candidate Pathogenic Factors
    Journal of Biological Chemistry, vol. 281, no. 42, pp. 31408–31418, 2006
29. Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA)
    Molecular & Cellular Proteomics, vol. 5, no. 9, pp. 1610–1627, 2006
30. Laser-capture microdissection
    Nature Protocols, vol. 1, no. 2, Article ID nprot.2006.85, 17 pages, 2006
31. The blood peptidome: a higher dimension of information content for cancer biomarker discovery
    Nature Reviews Cancer, vol. 6, no. 12, Article ID nrc2011, 6 pages, 2006
32. Identification and Characterization of Endogenous Langerin Ligands in Murine Extracellular Matrix
    Journal of Investigative Dermatology, vol. 126, no. 7, Article ID 5700283, 9 pages, 2006
33. A control theoretic paradigm for cell signaling networks: a simple complexity for a sensitive robustness
    Current Opinion in Chemical Biology, vol. 10, no. 1, pp. 81–87, 2006
34. Nanoparticles: potential biomarker harvesters
    Current Opinion in Chemical Biology, vol. 10, no. 1, pp. 56–61, 2006
35. The amplified peptidome: the new treasure chest of candidate biomarkers
    Current Opinion in Chemical Biology, vol. 10, no. 1, pp. 50–55, 2006
36. Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles
    PROTEOMICS, vol. 6, no. 11, pp. 3243–3250, 2006
37. Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray
    Targeted Oncology, vol. 1, no. 3, pp. 151–167, 2006
38. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer
    The Journal of Pathology, vol. 208, no. 5, pp. 595–606, 2006
39. Bioconjugate Chemistry, vol. 17, no. 3, pp. 654–661, 2006
40. Journal of Proteome Research, vol. 5, no. 5, pp. 1261–1266, 2006
41. Technology Insight: pharmacoproteomics for cancer—promises of patient-tailored medicine using protein microarrays
    Nature Clinical Practice Oncology, vol. 3, no. 5, Article ID ncponc0485, 12 pages, 2006
42. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
    Experimental Hematology, vol. 34, no. 6, pp. 796–801, 2006
43. Glia Maturation Factor Gamma (GMFG): A Cytokine-Responsive Protein During Hematopoietic Lineage Development and Its Functional Genomics Analysis
    Genomics, Proteomics & Bioinformatics, vol. 4, no. 3, pp. 145–155, 2006
44. Protein pathway analysis in Clinical Proteomics using protein microarrays
    Drug Discovery Today: Technologies, vol. 2, no. 4, pp. 353–359, 2005
45. Bioconjugate Chemistry, vol. 16, no. 3, pp. 559–566, 2005
46. A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
    Arthritis & Rheumatism, vol. 52, no. 3, pp. 902–910, 2005
47. Manual exfoliation of fresh tissue obviates the need for frozen sections for molecular profiling
    Cancer, vol. 105, no. 6, pp. 483–491, 2005
48. Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy
    Bioscience Reports, vol. 25, no. 1-2, pp. 107–125, 2005
49. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis
    Clinica Chimica Acta, vol. 357, no. 2, pp. 180–183, 2005
50. A mathematical model of combination therapy using the EGFR signaling network
    Biosystems, vol. 80, no. 1, pp. 57–69, 2005
51. Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
    Molecular & Cellular Proteomics, vol. 4, no. 4, pp. 346–355, 2005
52. Pathology of the Future: Molecular Profiling for Targeted Therapy
    Cancer Investigation, vol. 23, no. 1, pp. 36–46, 2005
53. Proteomic analysis for the early detection and rational treatment of cancer--realistic hope?
    Annals of Oncology, vol. 16, no. 1, pp. 16–22, 2005
54. Modeling of Protein Signaling Networks in Clinical Proteomics
    Cold Spring Harbor Symposia on Quantitative Biology, vol. 70, no. 1, pp. 517–524, 2005
55. Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data
    CancerSpectrum Knowledge Environment, vol. 97, no. 4, pp. 310–314, 2005
56. A nondestructive molecule extraction method allowing morphological and molecular analyses using a single tissue section
    Laboratory Investigation, vol. 85, no. 11, Article ID 3700337, 12 pages, 2005
57. Physiological Mechanisms of Tumor-Cell Invasion and Migration
    Physiology, vol. 20, no. 3, pp. 194–200, 2005
58. Supra-additive Growth Inhibition by a Celecoxib Analogue and Carboxyamido-triazole Is Primarily Mediated through Apoptosis
    Cancer Research, vol. 65, no. 9, pp. 3853–3860, 2005
59. A Transforming Growth Factor-  Receptor-Interacting Protein Frequently Mutated in Human Ovarian Cancer
    Cancer Research, vol. 65, no. 15, pp. 6526–6533, 2005
60. Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma
    Clinical Cancer Research, vol. 11, no. 16, pp. 5847–5855, 2005
61. Mapping Molecular Networks Using Proteomics: A Vision for Patient-Tailored Combination Therapy
    Journal of Clinical Oncology, vol. 23, no. 15, pp. 3614–3621, 2005
62. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment
    Journal of Clinical Investigation, vol. 115, no. 5, pp. 1163–1176, 2005
63. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold
    Journal of Clinical Investigation, vol. 116, no. 1, pp. 26–30, 2005
64. Lipids in Health and Disease, vol. 4, no. 1, p. 5, 2005
65. CSF proteome: a protein repository for potential biomarker identification
    Expert Review of Proteomics, vol. 2, no. 1, pp. 57–70, 2005
66. Cancer proteomics: many technologies, one goal
    Expert Review of Proteomics, vol. 2, no. 5, pp. 693–703, 2005
67. Analysis of Albumin-Associated Peptides and Proteins from Ovarian Cancer Patients
    Clinical Chemistry, vol. 51, no. 10, pp. 1933–1945, 2005
68. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma
    Endocrine Related Cancer, vol. 12, no. 2, pp. 263–272, 2005
69. Drosophila Neoplasias: Clues Towards the Understanding of Human Cancers
    Current Genomics, vol. 6, no. 4, pp. 251–256, 2005
70. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics
    Pharmacogenomics, vol. 6, no. 6, pp. 647–653, 2005
71. Clarification in the Point/Counterpoint Discussion Related to Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Identification of Patients with Adenocarcinomas of the Prostate * Proteomic Pattern Complexity Reveals a Rich and Uncharted Continent of Biomarkers
    Clinical Chemistry, vol. 50, no. 8, pp. 1475–1477, 2004
72. High-resolution serum proteomic features for ovarian cancer detection
    Endocrine Related Cancer, vol. 11, no. 2, pp. 163–178, 2004
73. High-resolution serum proteomic patterns for ovarian cancer detection
    Endocrine Related Cancer, vol. 11, no. 4, pp. 583–584, 2004
74. Use of proteomic analysis to monitor responses to biological therapies
    Expert Opinion on Biological Therapy, vol. 4, no. 1, pp. 83–93, 2004
75. Clinical Proteomics and Biomarker Discovery
    Annals of the New York Academy of Sciences, vol. 1022, no. 1, pp. 295–305, 2004
76. Blasting into the Microworld of Tissue Proteomics: A New Window on Cancer: Commentary re S. A. Schwartz et al., Protein Profiling in Brain Tumors Using Mass Spectrometry: Feasibility of a New Technique for the Analysis of Protein Expression. Clin. Cancer Res., 10: 981-987, 2004.
    Clinical Cancer Research, vol. 10, no. 3, pp. 825–827, 2004
77. A Functional Polymorphism in RGS6 Modulates the Risk of Bladder Cancer
    Cancer Research, vol. 64, no. 18, pp. 6820–6826, 2004
78. Serum Proteomics in Cancer Diagnosis and Management *
    Annual Review of Medicine, vol. 55, no. 1, pp. 97–112, 2004
79. SERUM PROTEOMIC PROFILING CAN DISCRIMINATE PROSTATE CANCER FROM BENIGN PROSTATES IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2.5 AND 15.0 NG/ML
    The Journal of Urology, vol. 172, no. 4, pp. 1302–1305, 2004
80. Expression Microdissection
    Diagnostic Molecular Pathology, vol. 13, no. 4, pp. 207–212, 2004
81. Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection
    Toxicologic Pathology, vol. 32, no. 6, pp. 122–130, 2004
82. Application of Laser Capture Microdissection and Protein MicroArray Technologies in the Molecular Analysis of Airway Injury Following Pollution Particle Exposure
    Journal of Toxicology and Environmental Health Part A, vol. 67, no. 11, pp. 851–861, 2004
83. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer
    Current Opinion in Biotechnology, vol. 15, no. 1, pp. 24–30, 2004
84. Network-targeted combination therapy: a new concept in cancer treatment
    Drug Discovery Today: Therapeutic Strategies, vol. 1, no. 4, pp. 425–433, 2004
85. Mitochondrial proteome: Cancer-altered metabolism associated with cytochromec oxidase subunit level variation
    PROTEOMICS, vol. 4, no. 9, pp. 2789–2795, 2004
86. Lessons from Kitty Hawk: From feasibility to routine clinical use for the field of proteomic pattern diagnostics
    PROTEOMICS, vol. 4, no. 8, pp. 2357–2360, 2004
87. Molecular Technologies for Personalized Cancer Management
    JAMA: The Journal of the American Medical Association, vol. 291, no. 13, pp. 1644–1645, 2004
88. An investigation into the human serum“interactome”
    ELECTROPHORESIS, vol. 25, no. 9, pp. 1289–1298, 2004
89. Proteomic analysis of lymph
    PROTEOMICS, vol. 4, no. 3, pp. 753–765, 2004
90. Ovarian cancer detection by logical analysis of proteomic data
    PROTEOMICS, vol. 4, no. 3, pp. 766–783, 2004
91. Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP)
    PROTEOMICS, vol. 4, no. 3, pp. 812–818, 2004
92. Journal of Proteome Research, vol. 3, no. 2, pp. 209–217, 2004
93. Opportunities for Nanotechnology-Based Innovation in Tissue Proteomics
    Biomedical Microdevices, vol. 6, no. 3, pp. 231–239, 2004
94. Anoikis: Cancer and the homeless cell
    Nature, vol. 430, no. 7003, Article ID 430973a, 1 pages, 2004
95. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray
    Laboratory Investigation, vol. 84, no. 2, Article ID 3700051, 9 pages, 2004
96. Genomic and proteomic technologies for individualisation and improvement of cancer treatment
    European Journal of Cancer, vol. 40, no. 17, pp. 2623–2632, 2004
97. Biomarkers of ovarian tumours
    European Journal of Cancer, vol. 40, no. 17, pp. 2604–2612, 2004
98. Trapping radioactive carbon dioxide during cellular metabolic assays under standard culture conditions: description of a unique gas-capturing device
    Journal of Biochemical and Biophysical Methods, vol. 58, no. 2, pp. 119–124, 2004
99. Protein microarray detection strategies: focus on direct detection technologies
    Journal of Immunological Methods, vol. 290, no. 1-2, pp. 121–133, 2004
100. Proteomic approaches in cancer risk and response assessment
     Trends in Molecular Medicine, vol. 10, no. 2, pp. 59–64, 2004
101. Use of proteomic patterns to screen for gastrointestinal malignancies
     Surgery, vol. 135, no. 3, pp. 243–247, 2004
102. Clinical proteomics: Applications for prostate cancer biomarker discovery and detection
     Urologic Oncology: Seminars and Original Investigations, vol. 22, no. 4, pp. 322–328, 2004
103. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
     Cancer Cell, vol. 5, no. 1, pp. 103–103, 2004
104. Importance of disclosure of patent applications
     The Lancet, vol. 364, no. 9434, pp. 577–578, 2004
105. Protein microarrays: Meeting analytical challenges for clinical applications
     Cancer Cell, vol. 3, no. 4, pp. 317–325, 2003
106. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
     Cancer Cell, vol. 4, no. 6, pp. 437–450, 2003
107. Bioconjugate Chemistry, vol. 14, no. 4, pp. 703–706, 2003
108. Promising directions for the diagnosis and management of gynecological cancers
     International Journal of Gynecology & Obstetrics, vol. 83, pp. 203–209, 2003
109. Cancer's deadly signature
     Nature Genetics, vol. 33, no. 1, Article ID ng0103-10, 1 pages, 2003
110. Cancer: Out of air is not out of action
     Nature, vol. 423, no. 6940, Article ID 423593a, 2 pages, 2003
111. Clinical proteomics: Written in blood
     Nature, vol. 425, no. 6961, Article ID 425905a, 1 pages, 2003
112. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays
     PROTEOMICS, vol. 3, no. 11, pp. 2085–2090, 2003
113. Protein microarrays: Molecular profiling technologies for clinical specimens
     PROTEOMICS, vol. 3, no. 11, pp. 2091–2100, 2003
114. Signal pathway profiling of prostate cancer using reverse phase protein arrays
     PROTEOMICS, vol. 3, no. 11, pp. 2142–2146, 2003
115. Mitochondrial proteome: Altered cytochromec oxidase subunit levels in prostate cancer
     PROTEOMICS, vol. 3, no. 9, pp. 1801–1810, 2003
116. Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype
     Proceedings of the National Academy of Sciences, vol. 100, no. 20, pp. 11463–11468, 2003
117. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays
     Proceedings of the National Academy of Sciences, vol. 100, no. 24, pp. 14229–14234, 2003
118. Proteomic analysis for early detection of ovarian cancer: A realistic approach?
     International Journal of Gynecological Cancer, vol. 13, no. s2, pp. 133–139, 2003
119. Cancer diagnosis using proteomic patterns
     Expert Review of Molecular Diagnostics, vol. 3, no. 4, pp. 411–420, 2003
120. Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection
     Clinical Chemistry, vol. 49, no. 4, pp. 533–534, 2003
121. Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection Has Already Arrived * Drs. Petricoin and Liotta respond:
     Clinical Chemistry, vol. 49, no. 7, pp. 1227–1229, 2003
122. The Vision for a New Diagnostic Paradigm
     Clinical Chemistry, vol. 49, no. 8, pp. 1276–1278, 2003
123. Proteomic Evaluation of Archival Cytologic Material Using SELDI Affinity Mass Spectrometry Potential for Diagnostic Applications
     American Journal of Clinical Pathology, vol. 118, no. 6, pp. 870–876, 2002
124. Future Research Directions in Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group
     American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 2, pp. 236–246, 2002
125. Utility of reverse phase protein arrays: Applications to signalling pathways and human body arrays
     Briefings in Functional Genomics and Proteomics, vol. 1, no. 3, pp. 305–315, 2002
126. Soluble adhesion molecules: marker of pre-eclampsia and intrauterine growth restriction
     The Journal of Maternal-Fetal & Neonatal Medicine, vol. 12, no. 1, pp. 28–34, 2002
127. Clinical proteomics: translating benchside promise into bedside reality
     Nature Reviews Drug Discovery, vol. 1, no. 9, Article ID nrd891, 12 pages, 2002
128. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer
     PROTEOMICS, vol. 2, no. 1, pp. 76–84, 2002
129. Frozen protein arrays: A new method for arraying and detecting recombinant and native tissue proteins
     PROTEOMICS, vol. 2, no. 11, pp. 1489–1493, 2002
130. Journal of Mammary Gland Biology and Neoplasia, vol. 7, no. 4, pp. 433–440, 2002
131. Use of proteomic patterns in serum to identify ovarian cancer
     The Lancet, vol. 359, no. 9306, pp. 572–577, 2002
132. Genomics and proteomics: application of novel technology to early detection and prevention of cancer
     Cancer Detection and Prevention, vol. 26, no. 4, pp. 249–255, 2002
133. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics
     Urology, vol. 57, no. 4, pp. 160–163, 2001
134. Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies
     Current Therapeutic Research, vol. 62, no. 11, pp. 803–819, 2001
135. Nature, vol. 410, no. 6824, pp. 24–25, 2001
136. Nature, vol. 411, no. 6835, pp. 375–379, 2001
137. Clinical Proteomics: Personalized Molecular Medicine
     JAMA: The Journal of the American Medical Association, vol. 286, no. 18, pp. 2211–2214, 2001
138. Proteomic profiling of the cancer microenvironment by antibody arrays
     PROTEOMICS, vol. 1, no. 10, pp. 1271–1278, 2001
139. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front
     Oncogene, vol. 20, no. 16, Article ID 1204265, 8 pages, 2001
140. 2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers
     Molecular & Cellular Proteomics, vol. 1, no. 2, pp. 117–123, 2001
141. Recognition of Multiple Classes of Hepatitis C Antibodies Increases Detection Sensitivity in Oral Fluid
     Clinical and Diagnostic Laboratory Immunology, vol. 8, no. 6, pp. 1267–1270, 2001
142. Signal Pathways Which Promote Invasion and Metastasis: Critical and Distinct Contributions of Extracellular Signal-Regulated Kinase and Ral-Specific Guanine Exchange Factor Pathways
     Molecular and Cellular Biology, vol. 21, no. 17, pp. 5958–5969, 2001
143. IF-LCM: Laser capture microdissection of immunofluorescently defined cells for mRNA analysis
     Kidney International, vol. 58, no. 3, Article ID 4495496, 7 pages, 2000
144. Laser capture microdissection: Beyond functional genomics to proteomics
     Molecular Diagnosis, vol. 5, no. 4, pp. 301–307, 2000
145. CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-γ and Hsp70/Hsc70
     Oncogene, vol. 19, no. 38, pp. 4385–4395, 2000
146. A sensitive screening assay for secreted motility-stimulating factors
     Cell Motility and the Cytoskeleton, vol. 46, no. 4, pp. 279–284, 2000
147. Nature Reviews Genetics, vol. 1, no. 1, pp. 48–56, 2000
148. Breast Cancer Research, vol. 2, no. 1, p. 13, 1999